Antisense Therapeutics

  • M. Ian Phillips

Part of the Methods in Molecular Medicine™ book series (MIMM, volume 106)

Table of contents

  1. Front Matter
    Pages i-xii
  2. Introduction

    1. Front Matter
      Pages 1-1
    2. M. Ian Phillips
      Pages 3-10
    3. Y. Clare Zhang, Meghan M. Taylor, Willis K. Samson, M. Ian Phillips
      Pages 11-34
  3. Cardiovascular

    1. Front Matter
      Pages 35-35
    2. Patrick L. Iversen, Nicholas Kipshidze, Jeffrey W. Moses, Martin B. Leon
      Pages 37-50
    3. M. Ian Phillips, Birgitta Kimura
      Pages 51-67
    4. Sian E. Harding, Federica del Monte, Roger J. Hajjar
      Pages 69-82
  4. Cancer

    1. Front Matter
      Pages 83-83
    2. Rosanne M. Orr, F. Andrew Dorr
      Pages 85-111
    3. Ingo Tamm
      Pages 113-134
    4. Eric Wickstrom, Xiaobing Tian, Nariman V. Amirkhanov, Atis Chakrabarti, Mohan R. Aruva, Ponugoti S. Rao et al.
      Pages 135-191
    5. Kazunori Aoki, Shumpei Ohnami, Teruhiko Yoshida
      Pages 193-204
  5. Blood—Brain Barrier

    1. Front Matter
      Pages 235-235
    2. Laura B. Jaeger, William A. Banks
      Pages 237-251
  6. Dermal

    1. Front Matter
      Pages 253-253
    2. Rhonda M. Brand, Patrick L. Iversen
      Pages 255-269
  7. Drugs

    1. Front Matter
      Pages 271-271
  8. Gastrointestinal

    1. Front Matter
      Pages 293-293
  9. Hepatitis

  10. Back Matter
    Pages 323-327

About this book


Announcement of the complete sequencing of the human genome in April 2003 demonstrated the presence of thousands of targets for antisense oligonucleotides and opened the way to hundreds of preclinical animal studies and some 20 ongoing clinical trials. In this second edition of Antisense Therapeutics, a team of leading researchers and clinical scientists demonstrate the new reality of antisense and RNA inhibition for treating a broad range of diseases. The authors show how antisense oligonucleotides are being designed and studied in relation to hypertension, various cancers, inflammatory bowel disease, brain disorders, the blood-brain barrier, and drug delivery. Highlights include RNA-based therapies for many diseases, up-to-date methods and applications, and insight into the enormous potential to provide a new generation of drugs.
Highly practical and disease oriented, Antisense Therapeutics, Second Edition offers not only a primer for a new generation of drug discovery researchers, but also an illuminating exploration of the potential in exploiting RNA inhibition for novel human therapeutics.


RNA apoptosis cancer cancer therapy cell drug drug delivery drug resistance hepatitis metabolism nucleic acid research resistance ribozyme siRNA

Editors and affiliations

  • M. Ian Phillips
    • 1
  1. 1.Vice President for ResearchUniversity of South FloridaTampa

Bibliographic information

  • DOI
  • Copyright Information Humana Press 2005
  • Publisher Name Humana Press
  • eBook Packages Springer Protocols
  • Print ISBN 978-1-58829-205-6
  • Online ISBN 978-1-59259-854-0
  • Series Print ISSN 1543-1894
  • Series Online ISSN 1940-6037
  • Buy this book on publisher's site